A Randomised, Open Label, Multi-centre, Phase III Study to Investigate the Efficacy of Bendamustine Compared to Treatment of Physician's Choice in the Treatment of Subjects With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab
Phase of Trial: Phase III
Latest Information Update: 30 Apr 2018
At a glance
- Drugs Bendamustine (Primary) ; Antineoplastics
- Indications B cell lymphoma; Follicular lymphoma; Marginal-zone-B-cell-lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms ROBIN
- Sponsors Mundipharma International
- 25 Apr 2018 Planned End Date changed from 31 Oct 2018 to 31 Dec 2018.
- 25 Apr 2018 Planned primary completion date changed from 31 Oct 2018 to 31 Dec 2018.
- 20 Jul 2017 Planned End Date changed from 1 Nov 2017 to 31 Oct 2018.